LIGAND PHARMACEUTICALS INCORPORATED Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of -$21.29 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2025-11-07
- LIGAND PHARMACEUTICALS INCORPORATED adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2025-09-30 was -$21.29M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month |
|---|---|
| 2025-09-30 | -$21.29M 10-Q · filed 2025-11-07 |